Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Tissue Biomarker Identified For Dementia With Lewy Bodies

By LabMedica International staff writers
Posted on 29 Apr 2016
Accurate diagnosis of Parkinson's disease, and the related disease "dementia with Lewy bodies," can be difficult in the early stages of both conditions. More...
While brain biopsies can be more accurate, the risk of complications has been considered too high.

A biopsy of the submandibular gland can help identify the same pathology that is seen in the brain, providing some of the increased accuracy of brain biopsy, but not the increased risk. It has previously been reported, from autopsy and needle biopsy, that there is a high prevalence of submandibular gland synucleinopathy in Parkinson’s disease (PD).

Scientists at Banner Sun Health Research Institute (Sun City, AZ, USA) and their colleagues studied 228 autopsied histological specimens including those with Lewy body disorders included 46 with Parkinson's disease, 28 with dementia with Lewy bodies (DLB), nine with incidental Lewy-body disease, 33 with Alzheimer's disease with Lewy bodies, and two with progressive supranuclear palsy with Lewy bodies (PSPLB). Control subjects, defined as individuals without central-nervous-system Lewy-type synucleinopathy (LTS), included 79 normal elderly subjects, 15 with Alzheimer's disease, 12 with progressive supranuclear palsy, two with corticobasal degeneration and two with multiple system atrophy (MSA).

Submandibular gland sections from autopsied subjects were stained with an immunohistochemical method for α-synuclein phosphorylated at serine 129. The investigators found submandibular gland alpha-synuclein pathology in 42/47 (89%) of autopsies of individuals with Parkinson's disease and 20/28 (71%) of those with dementia with Lewy bodies, but in none of the 110 control subjects. The authors concluded that their results provide support for further clinical trials of in vivo submandibular gland diagnostic biopsy for PD and DLB. An accurate peripheral biopsy diagnosis would assist subject selection for clinical trials and could also be used to verify other biomarkers.

Thomas G. Beach, MD, PhD, the lead investigator said, “The low diagnostic accuracy, during life, for dementia with Lewy bodies, has made it difficult to conduct effective clinical trials of possibly helpful new drugs. With better diagnostic accuracy, clinical trials would have a higher chance of success and could be done more quickly and at lesser cost. The next step will be to do biopsies of the submandibular gland in living people with dementia with Lewy bodies to confirm these autopsy results.” The study was published on March 30, 2016, in the Journal of Parkinson's Disease.

Related Links:
Banner Sun Health Research Institute


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.